Mtb32 is a promising tuberculosis antigen for DNA vaccination in pre-and post-exposure mouse models

Gene Therapy

Volumn 19, Issue 5, 2012, Pages 570-575

  Ahn, S S ^a   Jeon, B Y ^b   Kim, K S ^a   Kwack, J Y ^b   Lee, E G ^b   Park, K S ^a   Sung, Y C ^a   Cho, S N ^b  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

DNA vaccine; Flt3 L; prophylactic model; therapeutic model; tuberculosis

Indexed keywords

AG85A ANTIGEN; ALPHA CRYSTALLIN; BCG VACCINE; DNA VACCINE; FLT3 L ANTIGEN; GAMMA INTERFERON; ISONIAZID; MPT64 ANTIGEN; MTB32 ANTIGEN; MTB39 ANTIGEN; MYCOBACTERIUM ANTIGEN; PSTS3 ANTIGEN; PYRAZINAMIDE; TBI10.4 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL LOAD; BACTERIOSTASIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RESPONSE; DNA IMMUNIZATION; FEMALE; IMMUNOGENICITY; IMMUNOSTIMULATION; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; DISEASE MODELS, ANIMAL; IMMUNITY, CELLULAR; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINES, DNA;

BACTERIA (MICROORGANISMS); MUS; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS;

EID: 84862121577     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.140     Document Type: Article

References (36)

1. World Health Organization. Global Tuberculosis Control-Surveillance, Planning, Financing, WHO Reports, 1. World Health Organization: Geneva, Switzerland, 2009.
2. Brewer TF. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 2000; 31 (Suppl 3): S64-S67. (Pubitemid 32269590)
3. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346: 1339-1345.
4. Andersen P, Doherty TM. TB subunit vaccines-putting the pieces together. Microbes Infect 2005; 7: 911-921.
5. Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N et al. Identification of human T-cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol 2008; 181: 7948-7957.
6. Lowrie DB. DNA vaccines for therapy of tuberculosis: where are we now? Vaccine 2006; 24: 1983-1989. (Pubitemid 43255138)
7. Ulmer JB, Liu MA, Montgomery DL, Yawman AM, Deck RR, DeWitt CM et al. Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination. Vaccine 1997; 15: 792-794. (Pubitemid 27287957)
8. Tanghe A, Lefèvre P, Denis O, D'Souza S, Braibant M, Lozes E et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. J Immunol 1999; 162: 1113-1119. (Pubitemid 29035442)
9. Delogu G, Li A, Repique C, Collins F, Morris SL. DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitinconjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect Immun 2002; 70: 292-302. (Pubitemid 34028630)
10. Yuan Y, Crane DD, Simpson RM, Zhu YQ, Hickey MJ, Sherman DR et al. The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Natl Acad Sci USA 1998; 95: 9578-9583. (Pubitemid 28506274)
11. Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KL et al. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNAvaccinated and tuberculosis-infected mice. Infect Immun 2007; 75: 941-949. (Pubitemid 46203459)
12. Dillon DC, Alderson MR, Day CH, Lewinsohn DM, Coler R, Bement T et al. Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun 1999; 67: 2941-2950. (Pubitemid 29244712)
13. Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004; 172: 7618-7628. (Pubitemid 38747626)
14. Hervas-Stubbs S, Majlessi L, Simsova M, Morova J, Rojas MJ, Nouzé C et al. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. Infect Immun 2006; 74: 3396-3407. (Pubitemid 43794530)
15. Ha SJ, Jeon BY, Youn JI, Kim SC, Cho SN, Sung YC. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Therapy 2005; 12: 634-638.
16. Zhu D, Jiang S, Luo X. Therapeutic effects of Ag85B and MPT64 DNA vaccines in a murine model of Mycobacterium tuberculosis infection. Vaccine 2005; 23: 4619-4624. (Pubitemid 41033377)
17. Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol 2005; 175: 633-639. (Pubitemid 41094942)
18. Hung CF, Hsu KF, Cheng WF, Chai CY, He L, Ling M et al. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res 2001; 61: 1080-1088. (Pubitemid 32174428)
19. Triccas JA, Shklovskaya E, Spratt J, Ryan AA, Palendira U, Fazekas de St Groth B et al. Effects of DNA-and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis. Infect Immun 2007; 75: 5368-5375. (Pubitemid 350033625)
20. Sailaja G, Husain S, Nayak BP, Jabbar AM. Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand. J Immunol 2003; 170: 2496-2507. (Pubitemid 36245639)
21. Ha SJ, Jeon BY, Kim SC, Kim DJ, Song MK, Sung YC et al. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis. Gene Therapy 2003; 10: 1592-1599.
22. Taylor JL, Turner OC, Basaraba RJ, Belisle JT, Huygen K, Orme IM. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun 2003; 71: 2192-2198. (Pubitemid 36368754)
23. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 2001; 69: 2773-2778. (Pubitemid 32332164)
24. Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, Doherty TM et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005; 174: 6332-6339. (Pubitemid 40663826)
25. Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400: 269-271. (Pubitemid 29334142)
26. Orme IM. Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 2006; 24: 2-19. (Pubitemid 41721096)
27. Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, Turner OC et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 2004; 72: 6622-6632. (Pubitemid 39425445)
28. Skeiky YA, Lodes MJ, Guderian JA, Mohamath R, Bement T, Alderson MR et al. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun 1999; 67: 3998-4007. (Pubitemid 29357020)
29. Hallengard D, Haller BK, Petersson S, Boberg A, Maltais AK, Isaguliants M et al. Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity. Vaccine 2011; 29: 839-848.
30. Kim KS, Jin DB, Ahn SS, Park KS, Seo SH, Suh YS et al. HIV-1 protease has a genetic T-cell adjuvant effect which is negatively regulated by proteolytic activity. J Virol 2010; 84: 7743-7749.
31. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011; 17: 189-194.
32. Rollenhagen C, Sörensen M, Rizos K, Hurvitz R, Bumann D. Antigen selection based on expression levels during infection facilitates vaccine development for an intracellular pathogen. Proc Natl Acad Sci USA 2004; 101: 8739-8744. (Pubitemid 38745841)
33. Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 1999; 67: 1702-1707. (Pubitemid 29144386)
34. Morris S, Kelley C, Howard A, Li Z, Collins F. The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine 2000; 18: 2155-2163. (Pubitemid 30129106)
35. Hoang TT, Nansen A, Roy S, Billeskov R, Aagaard C, Elvang T et al. Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosis. PLoS One 2009; 4: e5928.
36. Ha SJ, Kim DJ, Baek KH, Yun YD, Sung YC. IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization. J Immunol 2004; 172: 525-531.